Ranitidine and Rectal cancer metastatic - a phase IV clinical study of FDA data

Summary:

Rectal cancer metastatic is reported as a side effect among people who take Ranitidine (ranitidine), especially for people who are female, 30-39 old, have been taking the drug for 2 - 5 years also take Ciclosporin, and have Inflammatory bowel disease.

The phase IV clinical study analyzes which people have Rectal cancer metastatic when taking Ranitidine. It is created by eHealthMe based on reports of 233,168 people who have side effects when taking Ranitidine from the FDA, and is updated regularly.

What is Ranitidine?

Ranitidine has active ingredients of ranitidine. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 234,475 Ranitidine users. Check the latest studies of Ranitidine.

What is Rectal cancer metastatic?

Rectal cancer metastatic (cancer of rectum spreads to other) is found to be associated with 46 drugs and 102 conditions by eHealthMe. Check the latest studies of Rectal cancer metastatic.

On Jul, 15, 2026

233,168 people reported to have side effects when taking Ranitidine.
Among them, 18 people (0.01%) have Rectal cancer metastatic.

Could Ranitidine cause Rectal cancer metastatic?

Among these 18 people:

How long have people been on Ranitidine when they have Rectal cancer metastatic? *

What is the gender of people who have Rectal cancer metastatic when taking Ranitidine? *

female: 88.89 %
male: 11.11 %

What is the age of people who have Rectal cancer metastatic when taking Ranitidine? *

What are other drugs people take besides Ranitidine? *

What are other side effects people have besides Rectal cancer metastatic? *

Maternal Exposure During Pregnancy (use of substance during pregnancy): 12 people, 66.67%
Bone Cancer Metastatic: 2 people, 11.11%
Colon Cancer: 2 people, 11.11%
Foetal Death (death of foetus): 2 people, 11.11%
Metastatic Lymphoma (spreadable cancer tumour of lymph node): 2 people, 11.11%
Intestinal Mass: 1 person, 5.56%
Anal Cancer: 1 person, 5.56%
Colon Cancer Stage Iv: 1 person, 5.56%
Colorectal Cancer Stage Iv (cancer of colon and rectal spreads to liver or lung): 1 person, 5.56%
Female Genital Tract Fistula (passage in genital tract of female): 1 person, 5.56%

What are the existing conditions these people have? *

Inflammatory Bowel Disease: 15 people, 83.33%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 5.56%
Abdominal Discomfort: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Ranitidine and have Rectal cancer metastatic?

- Check whether Rectal cancer metastatic is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ranitidine:

Ranitidine (234,475 reports)

Browse all side effects of Ranitidine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rectal cancer metastatic:

Rectal cancer metastatic (46 drugs)

Browse all the conditions that are associated with Rectal cancer metastatic:

Rectal cancer metastatic (102 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ranitidine (the active ingredients of Ranitidine) and Ranitidine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.